A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-22 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In 1660, German scientist Otto von Guericke studied static electricity by building a device comprising a large, rotating sulfur globe, now regarded as the first electrostatic generator. Sulfur appeared in the 1718 "affinity table" of the French chemist Étienne-François Geoffroy, a document that would become influential in chemistry works of the 18th century. Also present in that table was the so-called "Sulfur Principle": at the time, many chemists were convinced that sulfur was not a standalone element but instead contained multiple substances, including a distinct flammable one. This was supported by the phlogiston theory of combustion, which had emerged few decades prior; Geoffroy would later consider the sulfurous principle in his table to be phlogiston. Widely accepted for a century, phlogiston theory was debunked by the work of Antoine Lavoisier on combustion and oxygen. Antoine Lavoisier used sulfur in his combustion experiments, writing of some of these in 1777. In his 1789 Traité Élémentaire de Chimie, considered to be the first modern chemistry textbook, Lavoisier placed sulfur as its own chemical element in a "table of simple substances".
During the trial of alleged 9/11 conspirator Zacarias Moussaoui, the U.S. government identified five people as having been completely aware of the operation's details; bin Laden, Mohammed, Mohammed Atef, Abu Turab al-Urduni, and bin al-Shibh. The attacks were conceived by Khalid Sheikh Mohammed, who first presented it to bin Laden in 1996. Many targets were listed that al-Qaeda hijackers could crash planes into, including the Library Tower (now the U.S. Bank Tower) in Los Angeles. Bin Laden rejected the plan for being too elaborate. Al-Qaeda's first attacks against the U.S. after Bin Laden's 1998 fatwa were the 1998 African embassy bombings. In late 1998 or early 1999, bin Laden approved Mohammed to go forward with a new version of the 1996 plan. Bin Laden provided leadership and financial support, and was involved in selecting participants. Atef provided operational support, including target selections and helping arrange travel for the hijackers. He initially selected Nawaf al-Hazmi and Khalid al-Mihdhar, both experienced jihadists who had fought in the Bosnian war. The two arrived in the United States in mid-January 2000. In early 2000, they took flying lessons in San Diego, California. Both spoke little English. They performed poorly in flying lessons, and so they eventually served as secondary "muscle" hijackers. The Hamburg cell in Germany included Islamists who were key operatives in the 9/11 attacks. In late 1999, cell members bin al-Shibh, Mohamed Atta, Marwan al-Shehhi, and Ziad Jarrah arrived to meet al-Qaeda in Afghanistan.
=== BMSS Medal === In 2002 the BMSS Medal was established by the society “to recognise sustained contributions by individual members of the British Mass Spectrometry Society to the development of mass spectrometry, primarily within the UK.”
=== 2011–2016: The Devil Put Dinosaurs Here === On March 21, 2011, Alice in Chains announced that they were working on a fifth studio album, and both Cantrell and Inez later made statements that they had begun the recording process. The album was expected to be finished by summer of 2012 and released by the end of 2012 or beginning of 2013. While Alice in Chains were writing for the album in 2011, Cantrell underwent surgery on his right shoulder, which delayed recording the new material. In an interview published in May 2012, Cantrell explained, "The thing that set me back is I had some bone spurs [and] cartilage issues in my shoulders. I had the same issue in the other shoulder about six years ago so I've had them both done now. It's a repetitive motion injury from playing." Cantrell could not play guitar for eight months while he was recovering from surgery. While recuperating at home in a sling, Cantrell heard a riff in his head and sang it into his phone. The riff later became the song "Stone". Alice in Chains played their first concert in nearly 10 months and their first concert after Cantrell's shoulder surgery at the Winstar Casino in Thackerville, Oklahoma on August 13, 2011. The band's only concert in 2012 was a five-song acoustic set on May 31 at the eighth annual MusiCares MAP Fund Benefit Concert honoring Jerry Cantrell.
A form of tofu may have been discovered during the Han dynasty (202 BC – AD 220), but it did not become a popular food in China until the Song dynasty (960–1279). In China, tofu was traditionally eaten at the graves of deceased relatives. Ghosts were said to have long since lost their chins and jaws, so only tofu was soft enough for them to eat. Before the advent of refrigeration in China, tofu was usually sold only in the winter because it did not spoil easily in cold weather. In the warmer months, once made, tofu would spoil if left for more than a day.
Sources: en.wikipedia.org
== Relevance to the origin of life == The Miller–Urey experiment was proof that the building blocks of life could be synthesized abiotically from gases, and introduced a new prebiotic chemistry framework through which to study the origin of life. Simulations of protein sequences present in the last universal common ancestor (LUCA), or the last shared ancestor of all extant species today, show an enrichment in simple amino acids that were available in the prebiotic environment according to Miller–Urey chemistry. This suggests that the genetic code from which all life evolved was rooted in a smaller suite of amino acids than those used today. Thus, while creationist arguments focus on the fact that Miller–Urey experiments have not generated all 22 genetically-encoded amino acids, this does not actually conflict with the evolutionary perspective on the origin of life.
During the 1950s and 1960s, CSL produced semisynthetic penicillin as well. Penicillin was also produced by F.H. Faulding in South Australia, Abbott Laboratories in New South Wales and Glaxo in Victoria. By the 1970s there was a worldwide glut of penicillin. Glaxo ceased production in 1975 followed by CSL in 1980.
The avian circulatory system is driven by a four-chambered, myogenic heart contained in a fibrous pericardial sac. This pericardial sac is filled with a serous fluid for lubrication. The heart itself is divided into a right and left half, each with an atrium and ventricle. The atrium and ventricles of each side are separated by atrioventricular valves which prevent back flow from one chamber to the next during contraction. Being myogenic, the heart's pace is maintained by pacemaker cells found in the sinoatrial node, located on the right atrium. The sinoatrial node uses calcium to cause depolarisation of the signal transduction pathway from the atrium through right and left atrioventricular bundle which communicates contraction to the ventricles. The avian heart also consists of muscular arches that are made up of thick bundles of muscular layers. Much like a mammalian heart, the avian heart is composed of endocardial, myocardial and epicardial layers. The atrium walls tend to be thinner than the ventricle walls, due to the intense ventricular contraction used to pump oxygenated blood throughout the body. Avian hearts are generally larger than mammalian hearts when compared to body mass. This adaptation allows more blood to be pumped to meet the high metabolic need associated with flight.
== Expression == In insects, CSPs are found throughout the whole insect development process from eggs and larvae to nymphal and adult stages [4, 16-19]. In locusts, they are mainly expressed in the antennae, tarsi and legs, and found to be associated with phase change [3-4, 20-22]. CSPs are not the apanage of insects. They are also expressed in many various organisms such as crustacean, shrimp and many other arthropod species [23]. However, they are not specific to the arthropod kingdom. They are also expressed at the level of the bacterial superkingdom, demonstrating their existence not only in eukaryotes, but also in prokaryote organisms [23-24]. Prokaryote CSPs are twins or identical twins to insect CSPs [24]. They have been reported from bacterial species such as coccobacillus Acinetobacter baumannii, Macrococcus/Staphylococcus caseolyticus, the filamentous actinomycete Kitasatospora griseola, an Actinobacteria genus in the family Streptomycetaceae, and Escherichia coli (E. coli) which are known as common bacteria from the digestive tract, main prokaryotic secondary metabolites, opportunistic multi-drug resistant pathogens, high positive cytochrome c oxidase reactions, and symbionts of multiple insect species [24]. Their existence has been mentioned in plants, but this still needs to be demonstrated experimentally [25-26]. CSPs can be extracted from wasp venom [27]. In moths, nearly all CSPs are expressed in the female pheromone gland [9-14].
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.